FI112367B - Förfarande för framställing av polypeptidanaloger av ett baktericid/permeabilitet förbättrande protein eller biologiskt aktiva fragment därav eller ett hybridfusioprotein som innehåller detta och vidförfarandet användbara DNA-sekvenser, vektorer och värdceller - Google Patents

Förfarande för framställing av polypeptidanaloger av ett baktericid/permeabilitet förbättrande protein eller biologiskt aktiva fragment därav eller ett hybridfusioprotein som innehåller detta och vidförfarandet användbara DNA-sekvenser, vektorer och värdceller Download PDF

Info

Publication number
FI112367B
FI112367B FI953658A FI953658A FI112367B FI 112367 B FI112367 B FI 112367B FI 953658 A FI953658 A FI 953658A FI 953658 A FI953658 A FI 953658A FI 112367 B FI112367 B FI 112367B
Authority
FI
Finland
Prior art keywords
rbpi
protein
dna
bpi
cells
Prior art date
Application number
FI953658A
Other languages
English (en)
Finnish (fi)
Other versions
FI953658A0 (sv
FI953658A (sv
Inventor
Arnold Horwitz
David Burke
Georgia Theofan
Manik Baltaian
Lynn Grinna
Original Assignee
Xoma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Corp filed Critical Xoma Corp
Publication of FI953658A0 publication Critical patent/FI953658A0/sv
Publication of FI953658A publication Critical patent/FI953658A/sv
Application granted granted Critical
Publication of FI112367B publication Critical patent/FI112367B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4742—Bactericidal/Permeability-increasing protein [BPI]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)

Claims (16)

1. Förfarande för framställning av polypeptid-analoger av ett baktericid/permeabilitet förbättrande pro- 5 tein eller biologiskt aktiva fragment därav, i vilka cy-steinresten i position 132 har ersatts med en olik aminosy-ra, kännetecknat av att det innehäller steg i vilka man odlar en värdcell som har stabilt transformerats 10 eller transfekterats med DNA som kodar för nämnda polypep-tidanalog av det baktericida/permeabilitet förbättrande proteinet eller det biologiskt aktiva fragmentet därav i ett lämpigt odlingsmedium och isolerar nämnda polypeptid eller polypeptidianalog 15 frän nämnda värdcell eller nämnda odlingsmedium.
2. Förfarande enligt patentkrav 1, kännetecknat av att aminosyran som ersätter nämnda cys-teinrest är en icke-polar aminosyra, som väljs bland en grupp som innehäller alanin och serin. 20
3. Förfarande enligt patentkrav 1, känne tecknat av att alanin ersätter cysteinresten i position 132. I
4. Förfarande enligt patentkrav 1, 2 eller 3 kännetecknat av att nämnda protein eller poly-*. 25 peptidanalog innehäller, förutom ersättningen av cysteinet i position 132, 176 - 199 originella aminoterminala ami- » nosyrarester av det baktericida/permeabilitet förbättrande proteinet.
, 5. Förfarande enligt patentkrav 4, k ä n n e - » ; 30 tecknat av att nämnda protein eller polypeptid- » analog innehäller 193 originella aminoterminala aminosyra-; : rester av det baktericida/permeabilitet förbättrande pro teinet. » » 69 Π 2ό6'/
6. DNA, kännetecknad av att den kodar för en polypeptidanalog av ett baktericid/permeabilitet förbättrande protein eller ett biologiskt aktivt fragment därav, i vilka cysteinresten i position 132 har ersatts 5 med en olik aminosyra.
7. DNA enligt patentkrav 6, kännetecknad av att den kodar för en leader-sekvens med längden av 31 aminosyror och 193 första N-terminala rester av det baktericida/permeabilitet förbättrande proteinet och att 10 den innehäller ett slutkodon efter kodonet som befinner sig omedelbart efter det leucinresten i position 193 kodande kodonet.
8. DNA enligt patentkrav 6, kännetecknad av att den kodar för en leader-sekvens med längden 15 av 31 aminosyror och 193 första N-terminala rester av det baktericida/permeabilitet förbättrande proteinet och att den innehäller ett slutkodon efter kodonet som befinner sig omedelbart efter det isoleucinresten i position 199 kodande kodonet.
9. Autonomt replikerande DNA-vektor, k ä n n e - tecknad av att den innehäller en DNA enligt patentkrav 6.
; | 10. Värdcell, kännetecknad av att den ", har stabilt transformerats eller transfekterats med en DNA 25 enligt patentkrav 6 sä att expressionen av nämnda polypeptidanalog i nämnda värdcell blir möjlig.
11. Eukaryotisk värdcell, kännetecknad av att den är enligt patentkrav 10.
12. Värdcell enligt patentkrav 11, k ä n n e - , I 30 tecknad av att dess ATCC-kodnummer väljs bland ;· gruppen som innehäller kodnumren ATCC CRL 11246 och ATCC HB 11247.
13. Förfarande för framställning av ett hybrid-fusionsprotein, som innehäller aminoterminalt en polypepti- 35 danalog som producerats genom ett förfarande enligt patent-* krav 1 och karboxyterminalt ätminstone en konstant domän av 70 11266) immunoglobulins tunga kedja eller en allelisk variant dä-rav, kännetecknat av att det innehäller steg i vilka man odlar en värdcell som har stabilt transformerats 5 eller transfekterats med en DNA som kodar ett hybrid-fusionsprotein som innehäller aminoterminalt en polypepti-danalog, som producerats genom ett förfarande enligt pa-tentkrav 1 ooh karboxyterminalt ätminstone en konstant do-män av immunoglobulins tunga kedja eller en allelisk va-10 riant därav i ett lämpligt odlingsmedium och isolerar nämnda hybridfusionsprotein fran nämnda värdcell eller nämnda odlingsmedium.
14. DNA, kännetecknad av att den kodar för ett hybridfusionsprotein, som innehäller aminoter- 15 minalt en polypeptidanalog, som producerats genom ett förfarande enligt patentkrav 1 och karboxyterminalt ätminstone en konstant domän av immunoglobulins tunga kedja eller en allelisk variant därav.
15. Autonomt replikerande DNA-vektor, k ä n n e -20 tecknad av att den innehäller en DNA enligt patentkrav 14 .
16. Värdcell, kännetecknad av att den ; | har stabilt transformerats eller transfekterats med en DNA : enligt patentkrav 14 sä att expressionen av nämnda fusions- 25 polypeptid i nämnda värdcell blir möjlig. 1
FI953658A 1993-02-02 1995-08-01 Förfarande för framställing av polypeptidanaloger av ett baktericid/permeabilitet förbättrande protein eller biologiskt aktiva fragment därav eller ett hybridfusioprotein som innehåller detta och vidförfarandet användbara DNA-sekvenser, vektorer och värdceller FI112367B (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/013,801 US5420019A (en) 1993-02-02 1993-02-02 Stable bactericidal/permeability-increasing protein muteins
US1380193 1993-02-02
US9401235 1994-02-02
PCT/US1994/001235 WO1994018323A1 (en) 1993-02-02 1994-02-02 Stable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same

Publications (3)

Publication Number Publication Date
FI953658A0 FI953658A0 (sv) 1995-08-01
FI953658A FI953658A (sv) 1995-09-07
FI112367B true FI112367B (sv) 2003-11-28

Family

ID=21761817

Family Applications (2)

Application Number Title Priority Date Filing Date
FI953658A FI112367B (sv) 1993-02-02 1995-08-01 Förfarande för framställing av polypeptidanaloger av ett baktericid/permeabilitet förbättrande protein eller biologiskt aktiva fragment därav eller ett hybridfusioprotein som innehåller detta och vidförfarandet användbara DNA-sekvenser, vektorer och värdceller
FI20031199A FI115633B (sv) 1993-02-02 2003-08-26 DNA som kodar ett stabilt baktericida/permeabilitetsförbättrande proteinfragment, vektor, värdcell och förfarande för framställning av dessa proteinfragment

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI20031199A FI115633B (sv) 1993-02-02 2003-08-26 DNA som kodar ett stabilt baktericida/permeabilitetsförbättrande proteinfragment, vektor, värdcell och förfarande för framställning av dessa proteinfragment

Country Status (19)

Country Link
US (6) US5420019A (sv)
EP (3) EP0689592B1 (sv)
JP (4) JP4139867B2 (sv)
KR (1) KR100361997B1 (sv)
CN (1) CN1142996C (sv)
AT (3) ATE230797T1 (sv)
AU (1) AU693089B2 (sv)
CA (1) CA2155004C (sv)
DE (3) DE69426019T2 (sv)
DK (2) DK1310558T3 (sv)
ES (2) ES2288199T3 (sv)
FI (2) FI112367B (sv)
GR (1) GR3034492T3 (sv)
HK (1) HK1014548A1 (sv)
NO (3) NO315705B1 (sv)
NZ (1) NZ262284A (sv)
PT (2) PT689592E (sv)
WO (1) WO1994018323A1 (sv)
ZA (1) ZA94703B (sv)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US6265187B1 (en) * 1989-02-14 2001-07-24 Incyte Pharmaceuticals, Inc. Recombinant endotoxin-neutralizing proteins
US5840836A (en) * 1989-02-17 1998-11-24 Bayer Corporation Pancreatic islet cell antigens obtained by molecular cloning
US6811989B1 (en) * 1989-02-17 2004-11-02 Bayer Corporation Pancreatic islet cell antigens obtained by molecular cloning
AU4382193A (en) * 1992-05-19 1993-12-13 Xoma Corporation BPI-immunoglobulin fusion proteins
US6274348B1 (en) 1992-05-19 2001-08-14 Xoma Corporation Methods for the preparation of positively charged proteins
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
US6214789B1 (en) 1993-03-12 2001-04-10 Xoma Corporation Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products
DK0690720T3 (da) * 1993-03-12 2001-08-27 Xoma Technology Ltd Terapeutiske anvendelser af baktericide/permeabilitetsforøgende proteinprodukter
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
WO1995000641A1 (en) * 1993-06-17 1995-01-05 Xoma Corporation Lipopolysaccharide binding protein derivatives
WO1995002414A1 (en) * 1993-07-14 1995-01-26 Xoma Corporation Method for potentiating bpi protein product bactericidal activity by administration of lbp protein products
US5770561A (en) * 1993-07-14 1998-06-23 Xoma Corporation Method for potentiating BPI protein product bactericidal activity by administration of LBP protein products
DK0759774T3 (da) * 1993-09-22 2002-10-07 Xoma Technology Ltd Fremgangsmåde til behandling af gram-negativ bakteriel infektion ved indgivelse af baktericidt/permeabilitet-forøgende (BPI) proteinprodukt og antibiotikum
US6759203B1 (en) 1993-09-22 2004-07-06 Xoma Corporation Method for quantifying BPI in body fluids
CN1133634A (zh) * 1993-09-22 1996-10-16 爱克斯欧玛公司 定量体液中的bpi的方法
EP0754049B1 (en) * 1994-01-14 2002-04-03 XOMA Technology Ltd. Anti-fungal methods and materials
EP0754050B1 (en) * 1994-01-14 2002-06-26 XOMA Technology Ltd. Anti gram positive bacterial methods and materials
US5447913A (en) 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
US5786324A (en) * 1994-03-24 1998-07-28 Regents Of The University Of Minnesota Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
US5830860A (en) * 1994-03-24 1998-11-03 Regents Of The University Of Minnesota Peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
US5578568A (en) * 1994-04-22 1996-11-26 Xoma Corporation Method of treating conditions associated with intestinal ischemia/reperfusion
US6271203B1 (en) 1994-07-07 2001-08-07 Xoma Corporation Anti-protozoan methods and materials
US5646114A (en) * 1994-07-11 1997-07-08 Xoma Corporation Anti-protozoan methods
EP0795027A4 (en) * 1994-11-08 1999-03-10 Novagen Inc IN VITRO SYNTHESIS OF PROTEINS
US5494896A (en) * 1995-03-31 1996-02-27 Xoma Corporation Method of treating conditions associated with burn injuries
JP2001520631A (ja) * 1995-07-20 2001-10-30 ゾーマ コーポレイション 抗真菌性ペプチド
US5686414A (en) * 1995-11-14 1997-11-11 Xoma Corporation Methods of treating conditions associated with corneal transplantation
WO1997017990A1 (en) * 1995-11-14 1997-05-22 Xoma Corporation Bactericidal permeability increasing protein (bpi) for treating conditions associated with corneal injury
US5856159A (en) * 1996-03-27 1999-01-05 Cytel Corporation Production of galactosyltransferase
WO1997042966A1 (en) * 1996-05-10 1997-11-20 Xoma Corporation Therapeutic uses of bpi protein products for human meningococcemia
US5741779A (en) * 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
ATE234111T1 (de) * 1996-05-23 2003-03-15 Xoma Technology Ltd Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
JP2000511892A (ja) 1996-05-24 2000-09-12 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 可溶性ベーターシート形成性ペプチドの合成
US5888973A (en) 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
US6482796B2 (en) * 1996-11-01 2002-11-19 Xoma Corporation Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
CN1062564C (zh) * 1996-12-20 2001-02-28 周红 猪血中提纯杀菌性/通透性增加蛋白的方法
JP2001509167A (ja) * 1997-01-24 2001-07-10 エイブイアイ バイオファーマ，インコーポレイテッド Ｈ．ｐｙｌｏｒｉ感染を処置するための方法および結合体
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
FR2767323B1 (fr) * 1997-08-12 2001-01-05 Synt Em Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives
US6013631A (en) * 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
US6156514A (en) * 1998-12-03 2000-12-05 Sunol Molecular Corporation Methods for making recombinant cells
US6242219B1 (en) 1999-03-18 2001-06-05 Xoma (Us) Llc Methods for recombinant peptide production
US7041644B2 (en) * 1999-04-01 2006-05-09 Xoma Technology Therapeutic uses of BPI protein products in BPI-deficient humans
US6153584A (en) * 1999-04-01 2000-11-28 Levy; Ofer Therapeutic uses of BPI protein products in BPI-deficient humans
AU1431101A (en) 1999-10-04 2001-05-10 University Of Maryland Biotechnology Institute Novel adjuvant comprising a lipopolysaccharide antagonist
US20020173464A1 (en) * 2000-12-01 2002-11-21 King George L. Modulation of pericyte proliferation
US20030049616A1 (en) * 2001-01-08 2003-03-13 Sydney Brenner Enzymatic synthesis of oligonucleotide tags
US20030166063A1 (en) * 2001-03-05 2003-09-04 Harris Robert B. High level insect expression of rage proteins
AU2003211163A1 (en) 2002-02-20 2003-09-09 Regents Of The University Of Minnesota Partial peptide mimetics and methods
ES2557741T3 (es) * 2002-03-27 2016-01-28 Immunex Corporation Procedimientos para incrementar la producción de polipéptidos
DE60335794D1 (de) 2002-03-29 2011-03-03 Xoma Technology Ltd Multigene vectoren und methoden für eine erhöhte expression von rekombinanten polypeptiden
US7906722B2 (en) * 2005-04-19 2011-03-15 Palo Alto Research Center Incorporated Concentrating solar collector with solid optical element
EP1741440A1 (en) 2005-07-08 2007-01-10 Mellitus S.L. Use of BPI protein for the treatment of disorders of the metabolism and cardiovascular disorders
EP2592147A1 (en) 2007-10-12 2013-05-15 F. Hoffmann-La Roche AG Protein expression from multiple nucleic acids
WO2012138839A1 (en) 2011-04-05 2012-10-11 Dana-Farber Cancer Institute, Inc. Bpi and its congeners as radiation mitigators and radiation protectors
GB201319621D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Antimicrobial agents and their use in therapy
GB201319620D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Immunosuppressive agents and their use in therapy
RU2750721C2 (ru) 2017-03-10 2021-07-01 Ф. Хоффманн-Ля Рош Аг Способ получения мультиспецифических антител

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4853332A (en) * 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4816566A (en) * 1983-06-01 1989-03-28 Hoffmann-La Roche, Inc. Polypeptides having interferon activity
US4879226A (en) * 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
US4677063A (en) * 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4677064A (en) * 1984-11-09 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
DE3853918T2 (de) * 1987-08-11 1996-02-08 Univ New York Biologisch aktive bakterientötende/durchlässigkeitserhöhende proteinfragmente.
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US5576292A (en) * 1987-08-11 1996-11-19 New York University Biologically active bactericidal/permeability-increasing protein fragments
US5770694A (en) * 1990-08-13 1998-06-23 Incyte Pharmaceuticals, Inc. Genetically engineered BPI variant proteins
US5308834A (en) * 1989-02-14 1994-05-03 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and prevention thereof using a BPI protein
US5234912A (en) * 1989-02-14 1993-08-10 Incyte Pharmaceuticals, Inc. Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
US5334584A (en) * 1989-02-14 1994-08-02 Incyte Pharamaceuticals, Inc. Recombinant, non-glycosylated bpi protein and uses thereof
US5171739A (en) * 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
EP0563222B1 (en) * 1990-12-03 1998-02-25 New York University Biologically active bactericidal/permeability-increasing protein fragments
JPH07502642A (ja) * 1991-09-26 1995-03-23 インサイト　ファーマシューティカルズ，インコーポレイテッド 新規な形態のリポ糖結合性タンパク質（ｌｂｐ）
EP0565685B1 (en) * 1991-10-31 1997-05-14 LEE, Kwang Sil Electronic identification system having remote automatic response capability and automatic identification method thereof
US5439807A (en) * 1992-05-19 1995-08-08 Xoma Corporation Methods for the preparation of endotoxin-binding proteins
AU4382193A (en) * 1992-05-19 1993-12-13 Xoma Corporation BPI-immunoglobulin fusion proteins
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
CA2155005C (en) * 1993-02-02 1999-04-06 Weldon Courtney Mcgregor Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant
CA2157925C (en) * 1993-03-12 2000-06-06 Lewis H. Lambert, Jr. Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products
US5348942A (en) * 1993-03-12 1994-09-20 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products
ES2123134T3 (es) * 1993-03-12 1999-01-01 Xoma Corp Peptidos biologicamente activos de dominios funcionales de la proteina bactericida aumentadora de la permeabilidad y usos de los mismos.
DK0690720T3 (da) * 1993-03-12 2001-08-27 Xoma Technology Ltd Terapeutiske anvendelser af baktericide/permeabilitetsforøgende proteinprodukter
JPH08511682A (ja) * 1993-04-30 1996-12-10 インサイト ファーマシューティカルズ，インク． 組み換えｂｐｉ蛋白およびｌｂｐ蛋白、それをコードする核酸分子、その生産方法並びにそれらの使用

Also Published As

Publication number Publication date
FI20031199A (sv) 2003-08-26
US6828418B2 (en) 2004-12-07
NO20023224D0 (no) 2002-07-03
EP0689592B1 (en) 2000-09-27
PT1310558E (pt) 2007-09-07
EP1310558A3 (en) 2003-08-13
NO315705B1 (no) 2003-10-13
JP2006321813A (ja) 2006-11-30
NO20023224L (no) 1995-10-02
AU6170294A (en) 1994-08-29
KR100361997B1 (ko) 2003-04-08
CA2155004C (en) 2010-03-30
KR960700340A (ko) 1996-01-19
US5827816A (en) 1998-10-27
HK1014548A1 (en) 1999-09-30
DK1310558T3 (da) 2007-10-08
NO953033D0 (no) 1995-08-01
EP1310558B1 (en) 2007-05-30
US5420019A (en) 1995-05-30
ES2150983T3 (es) 2000-12-16
ZA94703B (en) 1994-09-05
JP4139867B2 (ja) 2008-08-27
DE69426019D1 (de) 2000-11-02
ATE196650T1 (de) 2000-10-15
DE69431995T2 (de) 2003-11-13
CN1142996C (zh) 2004-03-24
JPH08506586A (ja) 1996-07-16
EP0689592A1 (en) 1996-01-03
NO319156B1 (no) 2005-06-27
FI953658A0 (sv) 1995-08-01
JP2004024276A (ja) 2004-01-29
DE69431995D1 (de) 2003-02-13
EP1310558A2 (en) 2003-05-14
EP1013760A2 (en) 2000-06-28
JP2004254697A (ja) 2004-09-16
AU693089B2 (en) 1998-06-25
US20030109436A1 (en) 2003-06-12
CA2155004A1 (en) 1994-08-18
DK0689592T3 (da) 2000-10-16
DE69426019T2 (de) 2001-05-17
NO953033L (no) 1995-10-02
FI953658A (sv) 1995-09-07
EP1013760B1 (en) 2003-01-08
NO20050998L (no) 1995-10-02
ATE230797T1 (de) 2003-01-15
NZ262284A (en) 1997-11-24
PT689592E (pt) 2001-03-30
EP1013760A3 (en) 2000-08-09
ATE363535T1 (de) 2007-06-15
GR3034492T3 (en) 2000-12-29
FI115633B (sv) 2005-06-15
US6433140B1 (en) 2002-08-13
DE69434980T2 (de) 2008-01-24
ES2288199T3 (es) 2008-01-01
US20060009383A1 (en) 2006-01-12
WO1994018323A1 (en) 1994-08-18
DE69434980D1 (de) 2007-07-12
NO20050998D0 (no) 2005-02-24
CN1120352A (zh) 1996-04-10
US5674834A (en) 1997-10-07

Similar Documents

Publication Publication Date Title
FI112367B (sv) Förfarande för framställing av polypeptidanaloger av ett baktericid/permeabilitet förbättrande protein eller biologiskt aktiva fragment därav eller ett hybridfusioprotein som innehåller detta och vidförfarandet användbara DNA-sekvenser, vektorer och värdceller
WO1993023434A2 (en) Bpi-immunoglobulin fusion proteins
US5703038A (en) Therapeutic uses of bactericidal-permeability-increasing protein dimer products
KR20040063937A (ko) 재조합 폴리펩티드의 생산 방법
AU691175B2 (en) Novel polypeptide, DNA coding for said polypeptide, recombinant vector containing said DNA, recombinant virus prepared using said vector, and use thereof
CA2188423A1 (en) Factor interacting with nuclear proteins
US5861307A (en) Human s-myc-like polypeptide and a gene coding for said polypeptide
US5700690A (en) Compositions and methods for inhibiting fibrogenesis
AU776063B2 (en) Compositions and methods for the treatment of tumor
WO2000064933A1 (fr) Proteine inhibitrice d'activation transcriptionnelle
US6444801B1 (en) Transcriptional inhibitor protein and the encoding DNA
AU1737899A (en) Adenoviral transfer vector for the gene transport of a DNA sequence
US20060160732A1 (en) Compositions and methods for inhibiting cell senescence and hyperproliferative disorders
WO1998029544A9 (sv)